Categories
Nevin Manimala Statistics

Incidence of Acne in Women Using the Levonorgestrel-Releasing Intrauterine Device: A Systematic Review and Meta-Analysis

BJOG. 2025 Dec 22. doi: 10.1111/1471-0528.70108. Online ahead of print.

ABSTRACT

BACKGROUND: The levonorgestrel-releasing intrauterine system (LNG-IUS) is a widely used long-term contraceptive with high continuation rates, but acne may lead to discontinuation.

OBJECTIVES: To evaluate the incidence of acne among LNG-IUS users.

SEARCH STRATEGY: A systematic search was conducted in PubMed, Embase, and Cochrane Central from inception to September 2024.

SELECTION CRITERIA: Randomised clinical trials (RCTs) analysing patients of any age using LNG-IUS at 52 mg, 19.5 mg, or 13.5 mg, with acne reported as an outcome, were included.

DATA COLLECTION AND ANALYSIS: Statistical analyses were conducted using OpenMeta. Chi-square and Z-tests assessed differences between groups, and study quality was appraised using the ROB-2 tool.

MAIN RESULTS: Of 587 studies identified, nine RCTs met inclusion criteria, comprising 6305 LNG-IUS users. The overall acne incidence was 15.0% (95% CI 9.8%-20.3%). Among 2295 users of LNG-IUS 52 mg, incidence reached 19.5% (95% CI 5.2%-33.7%), whereas in 2322 users of LNG-IUS 13.5 mg it was 13.1% (95% CI 8.3%-17.9%) (p < 0.001). Two trials evaluated the 19.5 mg device but data were insufficient for pooling. Studies enrolling younger women (mean age ~24 years) reported an incidence of 19.3% (95% CI 11.0%-27.5%). Excluding Suhonen et al. yielded pooled proportions of 11.9% (95% CI 1.1%-22.7%) for LNG-IUS 52 mg users, 10.8% (95% CI 6.1%-15.5%) when all dosages were combined, and 9.9% (95% CI 9.0%-10.9%) among young women. Heterogeneity remained substantial in the overall and dosage-specific analyses (I2≈95%-97%); it was eliminated in the young women subgroup (I2 = 0%).

CONCLUSIONS: LNG-IUS 52 mg users showed a higher incidence of acne compared with those using LNG-IUS 13.5 mg. Studies enrolling younger women also showed a higher incidence. These findings suggest that device dosage and age influence acne occurrence among LNG-IUS users.

TRIAL REGISTRATION: PROSPERO registration number: CRD42024588771.

PMID:41424156 | DOI:10.1111/1471-0528.70108

By Nevin Manimala

Portfolio Website for Nevin Manimala